BioLife : Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea
November 15, 2017 at 04:45 pm EST
Share
15Nov
A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor - powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world's first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions the joints wears away, causing the bones to rub together and induce pain.
A single injection of the drug delivers therapeutic relief for up to two years, according to the firm. It was developed by Kolon Group's US-based bioparma subsidiary TissueGene, which went public on the Kosdaq recently. To read more, visit this article.
BioLife Solutions Inc. published this content on 15 November 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 November 2017 21:44:01 UTC.
Original documenthttps://www.biolifesolutions.com/uncategorized/kolon-life-science-launches-osteoarthritis-drug-invossa-korea/
Public permalinkhttp://www.publicnow.com/view/E9DE9ACF6ABE12BB23DCAACFDFFA21D3C8BBDBBA
BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to improve quality and de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. Its products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Its bioproduction tools and services are comprised of three lines: Cell processing, Freezers and thaw systems and Biostorage services. Its proprietary biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death. Its ThawSTAR line includes thawing products that control the temperature and timing of the thawing process of biologic material. It operates five storage facilities in the United States and one facility in the Netherlands.